In pediatric glioma research, GEMMs frequently incorporate mutations that disrupt key signaling pathways, including Ras, EGFR, Akt, Rb, PTEN, NF1, and PDGF signaling [4,8,72,89,178]. The gene discussed is NF1; the disease is central nervous system cancer.